D
Neurogene Inc. NGNE
$19.37 $0.130.68% NASDAQ
Recommendation
Prev Close
$19.24
Volume
78,513
Avg Vol (90D)
195,814
Market Cap
$298.02M
Dividend & Yield
--
52-Week Range
$6.88 - $37.27
P/E (TTM)
--
EPS (TTM)
-$4.12
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Neurogene (NGNE, $19.24) RSI Indicator left the oversold zone on December 02, 2025
12/3/2025 - Tickeron - Stocks
Neurogene (NGNE, $19.24) Aroon Indicator entered a Downtrend on December 02, 2025.
12/3/2025 - Tickeron - Stocks
Neurogene (NGNE) Shares Cross Below 200 DMA
12/2/2025 - Market News Video
Neurogene (NGNE, $20.48) Aroon Indicator entered a Downtrend on December 01, 2025.
12/2/2025 - Tickeron - Stocks
Neurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Hold" by Brokerages
12/1/2025 - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Hold" by Analysts
11/30/2025 - Ticker Report
Neurogene (NGNE, $20.44) RSI Indicator left the oversold zone on November 24, 2025
11/25/2025 - Tickeron - Stocks
Neurogene: From Speculation To Execution With NGN-401
11/24/2025 - SeekingAlpha
Neurogene: From Speculation To Execution With NGN-401
11/24/2025 - Seeking Alpha - Long Ideas
Neurogene (NGNE, $20.4) RSI Indicator left the oversold zone on November 20, 2025
11/21/2025 - Tickeron - Stocks
Neurogene (NGNE, $20.4) Aroon Indicator entered a Downtrend on November 20, 2025.
11/21/2025 - Tickeron - Stocks
Neurogene (NGNE, $20.99) Aroon Indicator entered a Downtrend on November 19, 2025.
11/20/2025 - Tickeron - Stocks
FY2025 EPS Estimates for Neurogene Increased by Analyst
11/20/2025 - MarketBeat
Neurogene (NGNE, $21.36) Aroon Indicator entered a Downtrend on November 18, 2025.
11/19/2025 - Tickeron - Stocks
Neurogene (NGNE, $22.46) Aroon Indicator entered a Downtrend on November 17, 2025.
11/18/2025 - Tickeron - Stocks
Commit To Purchase Neurogene At $12.50, Earn 15.8% Annualized Using Options
11/18/2025 - Stock Options Channel
Leerink Partnrs Forecasts Stronger Earnings for Neurogene
11/17/2025 - MarketBeat
Neurogene (NASDAQ:NGNE) Stock Rating Upgraded by Wall Street Zen
11/16/2025 - MarketBeat
Neurogene (NASDAQ:NGNE) Issues Quarterly Earnings Results
11/16/2025 - MarketBeat
Neurogene (NASDAQ:NGNE) Issues Quarterly Earnings Results
11/15/2025 - Zolmax
Neurogene (NASDAQ:NGNE) Price Target Raised to $70.00 at HC Wainwright
11/14/2025 - MarketBeat
Neurogene Reports Positive Interim Results for Rett Syndrome Gene Therapy
11/14/2025 - TipRanks Financial Blog
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
11/13/2025 - GuruFocus
Neurogene (NGNE) Advances with NGN-401 Gene Therapy and Strong Financial Position
11/13/2025 - GuruFocus
Neurogene reports Q3 EPS (99c) vs. ($1.19) last year
11/13/2025 - The Fly
Income Statement
Total Revenue (TTM)
$0.00
EBITDA (TTM)
-$94.21M
EBIT (TTM)
-$97.31M
Net Income (TTM)
-$85.13M
Balance Sheet
Total Assets (Q)
$287.83M
Total Debt (Q)
$10.21M
Total Liabilities (Q)
$22.29M
Book Value Per Share (Q)
$17.97
Cash Flow
Cash from Operations (TTM)
-$77.24M
Cash from Investing (TTM)
-$118.22M
Cash from Financing (TTM)
$199.83M
Net Change in Cash (TTM)
$4.37M
Filings
Filing Date
Thursday, November 13, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-3.44%
30-Day Total Return
-38.64%
60-Day Total Return
0.62%
90-Day Total Return
-10.66%
Year to Date Total Return
-15.38%
1-Year Total Return
-13.29%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 08, 2025 - $6.88
52-week High
Oct 16, 2025 - $37.27
Valuation
Market Cap
$298.02M - Micro Cap
Enterprise Value
$42.82M
Price/Sales (TTM)
--
Price/Book (Q)
1.07
Dividends and Shares
Shares Outstanding
21.17
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.neurogene.com
Phone Number
855 508 3568
Address
535 W 24th Street
New York, NY 10011
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an... more
NASDAQ 12/03/2025 2:06PM Eastern Quotes delayed